Document Detail

Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.
MedLine Citation:
PMID:  12222548     Owner:  NLM     Status:  MEDLINE    
Oral valganciclovir recently was approved by the Food and Drug Administration for treatment of cytomegalovirus (CMV) retinitis. We performed MEDLINE (June 1998-May 2002) and AIDSLINE (June 1998-December 2000) searches of available information on valganciclovir, and the drug's prescribing information was used to identify relevant articles. Additional studies, case reports, reviews, and abstracts were identified from references in the reviewed literature. Most of the information was obtained from abstracts or product labeling, since few trials have been published in the medical literature. Valganciclovir is a prodrug of ganciclovir and has been shown to have significantly higher oral absorption than ganciclovir capsules. One short-term study found valganciclovir to be as effective as intravenous ganciclovir in treating CMV retinitis. Recommended dosages for patients with normal renal function are valganciclovir 900 mg twice/day for induction and 900 mg once/day for maintenance. Side effects are similar to those of intravenous ganciclovir and require periodic monitoring of complete blood count and renal function. Given the need for lifelong therapy for CMV retinitis in some human immunodeficiency virus-positive patients, valganciclovir is a welcome alternative to long-term administration of intravenous antivirals.
Marisel Segarra-Newnham; Martha I Salazar
Related Documents :
1519558 - Effects of tokishakuyakusan, keishibukuryogan, shakuyakukanzoto and unkeito on ovarian ...
16818448 - Positive and negative regulations by fgf8 contribute to midbrain roof plate development...
20124268 - Omeprazole and clopidogrel: should clinicians be worried?
12222548 - Valganciclovir: a new oral alternative for cytomegalovirus retinitis in human immunodef...
23542048 - Possible ecosystem impacts of applying maximum sustainable yield policy in food chain m...
16702238 - Unexpectedly high activity of 228th in excretion samples following consumption of brazi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  22     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-09-11     Completed Date:  2003-03-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1124-8     Citation Subset:  IM    
Veterans Affairs Medical Center, Patient Support Service, West Palm Beach, Florida 33410-6400, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage,  adverse effects,  economics,  pharmacokinetics,  pharmacology,  therapeutic use*
Clinical Trials as Topic
Cytomegalovirus Retinitis / drug therapy*,  economics
Drug Interactions
Ganciclovir / administration & dosage,  adverse effects,  analogs & derivatives,  economics,  pharmacokinetics,  pharmacology,  therapeutic use*
HIV Seropositivity / complications*,  economics
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Antiviral Agents; 0/valganciclovir; 82410-32-0/Ganciclovir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world...
Next Document:  Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.